XML 48 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
Note 6 - Composition of Certain Financial Statement Captions (Tables)
12 Months Ended
Dec. 31, 2023
Notes Tables  
Condensed Balance Sheet [Table Text Block]
  

For the years ended December 31,

 

(In thousands)

 

2023

  

2022

 

Accounts receivable, net

        

Accounts receivable

 $125,379  $131,474 

Less: allowance for doubtful accounts

  (2,000)  (4,162)
  $123,379  $127,312 

Inventories, net

        

Finished products

 $35,582  $37,139 

Consumable supplies

  25,864   31,275 

Work in-process

  1,731   2,449 

Raw materials

  8,981   6,771 

Less: inventory reserve

  (6,461)  (3,574)
  $65,697  $74,060 

Other current assets and prepaid expenses

        

Prepaid supplies

 $6,177  $7,918 

Prepaid insurance

  3,848   4,496 

Taxes recoverable

  4,211   8,191 

Other receivables

  2,610   13,105 

Other

  7,673   6,252 
  $24,519  $39,962 

Property, plant and equipment, net:

        

Machinery, medical and other equipment

 $138,776  $136,048 

Leasehold improvements

  28,058   25,516 

Furniture and fixtures

  12,046   11,271 

Building

  18,885   18,314 

Software

  14,410   14,218 

Automobiles and aircraft

  12,701   12,808 

Land

  2,425   2,317 

Construction in process

  5,255   4,793 

Less: accumulated depreciation

  (157,127)  (142,406)
  $75,429  $82,879 

Intangible assets, net:

        

Technologies

 $831,509  $826,282 

Customer relationships

  315,799   314,854 

Trade names

  49,758   49,752 

Covenants not to compete

  12,916   12,911 

Licenses

  6,205   5,988 

Product registrations

  6,790   6,831 

Other

  6,000   5,861 

Less: accumulated amortization

  (488,694)  (398,959)
  $740,283  $823,520 
  

For the years ended December 31,

 

(In thousands)

 

2023

  

2022

 

Accrued expenses:

        

Employee benefits

 $28,952  $33,765 

Gross to net provision

  9,420   6,477 

Inventory received but not invoiced

  1,653   7,830 

Taxes payable

  1,384   5,351 

Commitments and contingencies

  8,088   4,295 

Clinical trials

  7,624   4,700 

Finance leases short-term

  2,827   2,809 

Royalties

  1,544   2,323 

Professional fees

  3,470   1,820 

Commissions

  1,822   1,471 

Contingent consideration

     62 

Contract liabilities

      

Other

  23,302   27,366 
  $90,086  $98,269 

Other long-term liabilities:

        

Mortgages and other debts payable

 $7,709  $9,098 

Finance leases long-term

  7,274   7,089 

Contingent consideration

     974 

Contract liabilities

  7   138 

Other

  12,199   10,072 
  $27,189  $27,371 
Summary of Valuation Allowance [Table Text Block]
      

Charged

             
  

Beginning

  

to

      

Charged

  

Ending

 

(In thousands)

 

balance

  

expense

  

Written-off

  

to other

  

balance

 

2023

                    

Allowance for doubtful accounts

 $(4,162)  (247)  2,408     $(2,000)

Inventory reserve

 $(3,574)  (8,100)  5,213     $(6,461)

Tax valuation allowance

 $(279,212)  (11,128)     (4,223) $(294,563)

2022

                    

Allowance for doubtful accounts

 $(1,839)  (304)  (2,019)    $(4,162)

Inventory reserve

 $(4,779)  (4,059)  5,264     $(3,574)

Tax valuation allowance

 $(260,397)  (24,579)     5,764  $(279,212)
Schedule of Goodwill [Table Text Block]
  

2023

  

2022

 

(In thousands)

 

Gross goodwill at January 1

  

Cumulative impairment at January 1

  

Acquisitions, dispositions and other

  

Foreign exchange and other

  

Balance at December 31st

  

Gross goodwill at January 1

  

Cumulative impairment at January 1

  

Acquisitions, dispositions and other

  

Foreign exchange and other

  

Balance at December 31st

 

Pharmaceuticals

                                        

CURNA

 $4,827  $(4,827) $  $  $  $4,827  $(4,827) $  $  $ 

Rayaldee

  81,786         2,485   84,273   86,554         (4,768)  81,786 

FineTech

  11,698   (11,698)           11,698   (11,698)         

ModeX

  80,432      (172)     80,260         80,432      80,432 

OPKO Biologics

  139,784            139,784   139,784            139,784 

OPKO Chile

  3,767         (125)  3,642   3,760         7   3,767 

OPKO Health Europe

  7,057         219   7,276   7,478         (421)  7,057 

OPKO Mexico

  100   (100)           100   (100)         

Transition Therapeutics

  3,421   (3,421)           3,421   (3,421)         
                                         

Diagnostics

                                        

BioReference

  283,025            283,025   434,809      (151,784)     283,025 

OPKO Diagnostics

  17,977   (17,977)           17,977   (17,977)         
  $633,874  $(38,023) $(172) $2,579  $598,260  $710,408  $(38,023) $(71,352) $(5,182) $595,851